Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience
Purpose: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177 Lu DOTA-TATE therapy is a form of PRRT which targets Somatostatin Receptors (SSR). It is a form of targeted drug delivery, which is applicable to treat neuroendocrine tumors. PRRT applications are continuously expanding...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2025-01-01
|
| Series: | Frontiers in Biomedical Technologies |
| Subjects: | |
| Online Access: | https://fbt.tums.ac.ir/index.php/fbt/article/view/655 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863911494975488 |
|---|---|
| author | Elahe Mahmoudi Mahasti Amoui Mohammad Reza Deevband Elahe Pirayesh Mohammad Reza Asgari Mehdi Ghorbani |
| author_facet | Elahe Mahmoudi Mahasti Amoui Mohammad Reza Deevband Elahe Pirayesh Mohammad Reza Asgari Mehdi Ghorbani |
| author_sort | Elahe Mahmoudi |
| collection | DOAJ |
| description |
Purpose: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177 Lu DOTA-TATE therapy is a form of PRRT which targets Somatostatin Receptors (SSR). It is a form of targeted drug delivery, which is applicable to treat neuroendocrine tumors. PRRT applications are continuously expanding in most departments of nuclear medicine in Iran, but the best of all, no one has studied the mean doses of organs of the patients. This research aims to specify the absorbed dose to patients for the treatment of neuroendocrine tumors using imaging with 177Lu-[DOTA0-Tyr3] octerotate.
Materials and Methods: Whole body planar scintigraphy images were collected for 10 patients, which are used as the basis for the personalized patient dosimetry calculations. The patients had a mean age of 53.5 ± 12 years (ranging from 36 to 70 years) and imaging data were collected at roughly 0 to 2 hours, 4 to 6 hours, 18 to 24 hours, and 36 to 48 hours after the injection of 6401± 628.4 MBq (range of 5500 MBq-7400 MBq) of 177Lu-[DOTA0-Tyr3] octerotate. Models of time-activity were established for different organs. Finally, using absorbed dose formulation and IDIAC-Dosage software, the mean absorbed dose in the organs was determined.
Results: Mean calculated dose in the kidney and liver were obtained as 0.30-0.82 mGy/ MBq, and 1.05-2.11 mGy/MBq, respectively.
Conclusion: Based on the results, PRRT therapy is a safe method for the treatment of castration-resistant neuroendocrine cancer patients in terms of patient dose. Large inter-individual differences in organ dose were discovered, highlighting the importance of patient-specific dosimetry and treatment planning in the treatment with 177Lu-DOTATATE.
|
| format | Article |
| id | doaj-art-4d1fc4139f834dd8a3bd87784afed21a |
| institution | Kabale University |
| issn | 2345-5837 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Frontiers in Biomedical Technologies |
| spelling | doaj-art-4d1fc4139f834dd8a3bd87784afed21a2025-02-09T08:56:01ZengTehran University of Medical SciencesFrontiers in Biomedical Technologies2345-58372025-01-0112110.18502/fbt.v12i1.17731Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center ExperienceElahe Mahmoudi0Mahasti Amoui1Mohammad Reza Deevband2Elahe Pirayesh3Mohammad Reza Asgari4Mehdi Ghorbani5Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranNuclear Medicine Department, Shohada-e-Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranBiomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranNuclear Medicine Department, Shohada_e Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranBiomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranBiomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Purpose: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177 Lu DOTA-TATE therapy is a form of PRRT which targets Somatostatin Receptors (SSR). It is a form of targeted drug delivery, which is applicable to treat neuroendocrine tumors. PRRT applications are continuously expanding in most departments of nuclear medicine in Iran, but the best of all, no one has studied the mean doses of organs of the patients. This research aims to specify the absorbed dose to patients for the treatment of neuroendocrine tumors using imaging with 177Lu-[DOTA0-Tyr3] octerotate. Materials and Methods: Whole body planar scintigraphy images were collected for 10 patients, which are used as the basis for the personalized patient dosimetry calculations. The patients had a mean age of 53.5 ± 12 years (ranging from 36 to 70 years) and imaging data were collected at roughly 0 to 2 hours, 4 to 6 hours, 18 to 24 hours, and 36 to 48 hours after the injection of 6401± 628.4 MBq (range of 5500 MBq-7400 MBq) of 177Lu-[DOTA0-Tyr3] octerotate. Models of time-activity were established for different organs. Finally, using absorbed dose formulation and IDIAC-Dosage software, the mean absorbed dose in the organs was determined. Results: Mean calculated dose in the kidney and liver were obtained as 0.30-0.82 mGy/ MBq, and 1.05-2.11 mGy/MBq, respectively. Conclusion: Based on the results, PRRT therapy is a safe method for the treatment of castration-resistant neuroendocrine cancer patients in terms of patient dose. Large inter-individual differences in organ dose were discovered, highlighting the importance of patient-specific dosimetry and treatment planning in the treatment with 177Lu-DOTATATE. https://fbt.tums.ac.ir/index.php/fbt/article/view/655Individualized Dosimetry177Lu-DOTA0Tyr3-OctreotateNeuroendocrine TumorsOrgan at Risk |
| spellingShingle | Elahe Mahmoudi Mahasti Amoui Mohammad Reza Deevband Elahe Pirayesh Mohammad Reza Asgari Mehdi Ghorbani Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience Frontiers in Biomedical Technologies Individualized Dosimetry 177Lu-DOTA0 Tyr3-Octreotate Neuroendocrine Tumors Organ at Risk |
| title | Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience |
| title_full | Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience |
| title_fullStr | Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience |
| title_full_unstemmed | Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience |
| title_short | Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience |
| title_sort | internal dosimetry in patients undergoing peptide receptor radionuclide therapy prrt with 177lu dota0 tyr3 octerotate a single center experience |
| topic | Individualized Dosimetry 177Lu-DOTA0 Tyr3-Octreotate Neuroendocrine Tumors Organ at Risk |
| url | https://fbt.tums.ac.ir/index.php/fbt/article/view/655 |
| work_keys_str_mv | AT elahemahmoudi internaldosimetryinpatientsundergoingpeptidereceptorradionuclidetherapyprrtwith177ludota0tyr3octerotateasinglecenterexperience AT mahastiamoui internaldosimetryinpatientsundergoingpeptidereceptorradionuclidetherapyprrtwith177ludota0tyr3octerotateasinglecenterexperience AT mohammadrezadeevband internaldosimetryinpatientsundergoingpeptidereceptorradionuclidetherapyprrtwith177ludota0tyr3octerotateasinglecenterexperience AT elahepirayesh internaldosimetryinpatientsundergoingpeptidereceptorradionuclidetherapyprrtwith177ludota0tyr3octerotateasinglecenterexperience AT mohammadrezaasgari internaldosimetryinpatientsundergoingpeptidereceptorradionuclidetherapyprrtwith177ludota0tyr3octerotateasinglecenterexperience AT mehdighorbani internaldosimetryinpatientsundergoingpeptidereceptorradionuclidetherapyprrtwith177ludota0tyr3octerotateasinglecenterexperience |